Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Open Retatrutide (Reta) in the 3D analyzerAnalytical specification
| Empirical formula | C223H343N61O67S |
|---|---|
| Molecular weight | 4731.3 g/mol |
| Isoelectric point (pI) | 6.25 |
| Assay purity (HPLC) | 99.40% |
| Retention time | 5.65 min |
| Peak area / height | 13950 / 1150 |
| Reference batch | RE-2026-X12 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | Y-Aib-E-G-T-F-T-S-D-Y-S-I-Aib-L-D-K-I-A-Q-A-F-V-Q-W-L-I-A-G-G-P-S-S-G-A-P-P-P-S |
Research characteristics
Weight Reduction
Synergistic tri-agonist approach for maximum fat loss
Energy Expenditure
Glucagon activation increases baseline metabolic rate
Glucose Control
Superior HbA1c optimization vs single agonists
Hepatic Health
Significant reduction in liver fat accumulation
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.
Orforglipron
Non-peptide oral small-molecule GLP-1 receptor agonist engineered for high bio-availability trials.